Loading...
Loading...
NEW YORK, NY · CIK 0001263508
New positions
15
Added to
15
Trimmed
7
Exited
10
BAKER BROS. ADVISORS LP (NEW YORK, NY) reported a portfolio value of $7.97B across 89 positions in their Q1 2024 SEC 13F filing (period ending 2024-03-31). The top 10 positions account for 77.1% of the portfolio.
Top 30 holdings by portfolio weight. Block width = holding percentage. Green = new/increased, red = reduced, gray = unchanged.
| # | Stock | Value↓ | Weight | Change |
|---|---|---|---|---|
| 1 | INCYIncyte Corporation | $2.06B | 25.86% | +0.0% |
| 2 | ONCBeiGene, Ltd. | $1.65B | 20.73% | - |
| 3 | ACADACADIA Pharmaceuticals Inc. | $792.57M | 9.94% | - |
| 4 | MDGLMadrigal Pharmaceuticals, Inc. | $526.01M | 6.60% | - |
| 5 | RYTMRhythm Pharmaceuticals, Inc. | $277.24M | 3.48% | - |
| 6 | RVMDRevolution Medicines, Inc. | $243.31M | 3.05% | +46.6% |
| 7 | KYMRKymera Therapeutics, Inc. | $241.04M | 3.02% | - |
| 8 | ABCLAbCellera Biologics Inc. | $124.69M | 1.56% | +20.1% |
| 9 | BCYCBicycle Therapeutics plc | $123.08M | 1.54% | +176.1% |
| 10 | EWTXEdgewise Therapeutics, Inc. | $106.52M | 1.34% | +87.6% |
| Stock | Value | Shares |
|---|---|---|
| FATEFate Therapeutics, Inc. | $13.35M | 1,818,181 |
| NMRANeumora Therapeutics, Inc. | $8.72M | 633,851 |
| DYNDyne Therapeutics, Inc. | $8.09M | 285,000 |
| PRAXPraxis Precision Medicines, Inc. | $8.03M | 131,533 |
| SG7Sage Therapeutics, Inc. | $7.63M | 407,217 |
| NVLSEURAlpine Immune Sciences, Inc. | $3.23M | 81,578 |
| FDMT4D Molecular Therapeutics, Inc. | $3.19M | 100,000 |
| FDMT4D Molecular Therapeutics, Inc. | $3.19M | 100,000 |
| NAMSNewAmsterdam Pharma Company N.V. | $2.29M | 96,827 |
| VTVTvTv Therapeutics, Inc. | $2.29M | 97,314 |
Get alerts when BAKER BROS. ADVISORS LP files new 13F holdings.